title: [Study on etoposide therapy of relapsing prostatic cancer patients].
abstract: Eight patients with hormone resistant prostate cancer were treated with 30 mg/m2 etoposide every two or three weeks. A response rate of 37.5% in clinical status was noted. Slight toxicity was seen temporarily. We think this etoposide therapy is a useful regimen for advanced or relapsing carcinoma of the prostate.
authors.affiliation: Department of Urology, Kanagawa Prefectural Cancer Center.
authors.forename: M
authors.initials: M
authors.lastname: Moriyama
authors.forename: T
authors.initials: T
authors.lastname: Murai
authors.forename: I
authors.initials: I
authors.lastname: Kondoh
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000368:Aged; D000369:Aged, 80 and over; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D005047:Etoposide